ArticleCancer science2010

Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.

Takeru Nambu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.